The Essentials
- The standard of care: Oncology infusion therapy is the intravenous delivery of chemotherapy, immunotherapy, Hormonal, biologics and supportive medications, and remains the default route for most systemic cancer treatment. In Riyadh it runs in cycles of 1 to 3 weeks for 3 to 6 months, with sessions lasting 1 to 6 hours.
The overlooked factor: Outcomes are shaped just as heavily by where treatment is delivered as by the drug itself. Oncology pharmacist oversight, certified chemotherapy nursing and continuity with the treating oncologist are the real drivers of safety and comfort.
The right care pathway: Choosing where your treatment is administered is not a price decision. Quality accreditation, oncology trained nursing and pharmacist oversight, and seamless coordination with your treating oncologist determine real value, with most patients covered through public care or CCHI compliant insurance.
Oncology Infusion Therapy
Oncology infusion therapy is the delivery medication directly into the bloodstream through a vein. It is the standard route for most systemic cancer therapies because it allows precise dosing, faster absorption and closer clinical monitoring than tablets alone.
According to the American Cancer Society, most chemotherapy regimens worldwide are given intravenously, along with the majority of immunotherapies, monoclonal antibodies and targeted biologic agents in modern oncology.
In Riyadh, infusion therapy now sits at the heart of cancer care, and it no longer means a long stay in hospital. The shift to day care units and patient centered specialist centres, including IV One Health Centre, has made treatment more accessible, far more comfortable and easier to fit around family life.
Types of Oncology Infusions Delivered in Riyadh
Cancer infusion therapy is not a single treatment. It is a category of treatments that vary by drug class, mechanism of action, duration and care setting. The table below summarises the main categories delivered across Riyadh’s oncology infusion centres.
| Infusion Type | Purpose | Typical Session Length | Frequency | Common Use Cases |
| Chemotherapy | Destroys rapidly dividing cancer cells | 1 to 6 hours | Every 1 to 3 weeks | Breast, colorectal, lung, lymphoma, leukaemia |
| Immunotherapy | Activates the immune system to attack cancer | 30 to 90 minutes | Every 2 to 6 weeks | Melanoma, lung, kidney, bladder, head and neck |
| Targeted biologics | Blocks specific cancer growth pathways | 30 minutes to 4 hours | Every 1 to 3 weeks | HER2 positive breast, colorectal, certain leukaemias |
| Monoclonal antibodies | Marks cancer cells for immune destruction | 1 to 4 hours | Every 2 to 4 weeks | Lymphoma, multiple myeloma, breast cancer |
| Hormone modulators (IV) | Suppresses hormone driven cancer growth | 15 to 30 minutes | Every 4 to 12 weeks | Prostate, certain breast cancers |
| Bone modifying agents | Strengthens bone and prevents skeletal events | 15 to 30 minutes | Every 4 to 12 weeks | Bone metastases, multiple myeloma |
| Supportive infusions | Manages side effects and recovery | 30 to 60 minutes | As needed | Hydration, anti nausea, electrolyte correction, blood products |
Treatment plans are rarely single agents. Most patients in Riyadh receive a combination protocol selected by their oncologist based on tumour type, stage, biomarker profile and overall health.
Why Riyadh has Become a Regional Hub for Oncology Infusion
Saudi Arabia has invested heavily in oncology infrastructure as part of Vision 2030 health sector reform. Riyadh in particular has emerged as a regional centre for advanced cancer care, supported by world ranked institutions, modern day care units and a tightly regulated private sector.
Three forces have shaped this position.
Investment in tertiary oncology. Institutions such as King Faisal Specialist Hospital and Research Centre , King Abdulaziz medical city and the King Fahad Medical City run high volume oncology programmes that match international clinical benchmarks.
Adoption of international standards. Most major Riyadh oncology providers hold accreditation from CBAHI domestically and from international bodies such as Joint Commission International. Treatment protocols largely follow National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines.
Shift to ambulatory care. Day care infusion has reduced average inpatient stays and freed bed capacity. The model mirrors trends documented by the World Health Organization which encourages outpatient oncology delivery in well resourced settings to improve patient experience without compromising safety.
IV One was built around this ambulatory model. Our Riyadh infusion suite is designed to deliver hospital grade oncology infusion in a calm, patient first environment, with full oncology pharmacist oversight and a direct working relationship with the oncologist who prescribed your treatment. We do not diagnose or change your plan, we administer it faithfully and well.
The Patient Journey: What to Expect from Oncology Infusion in Riyadh
The first few weeks after a cancer diagnosis can feel overwhelming. Understanding what each step of the infusion journey looks like, and why it happens, can lift a lot of that weight from patients and their families.
Step 1.
Diagnosis and staging: Lab investigations, Imaging, biopsy, and biomarker testing confirm cancer type and stage. This determines whether infusion therapy is appropriate, which protocol fits and how many cycles will be required.
Step 2.
Treatment planning: The medical oncologist/Hematologist designs a regimen based on ASCO and NCCN guidance, factoring in performance status, comorbidities and patient goals. The plan is reviewed in a multidisciplinary tumour board for most complex cases.
Step 3.
Vascular access: For longer regimens, a central venous access device such as a portacath or PICC line is inserted to protect peripheral veins and reduce discomfort across multiple cycles.
Step 4.
Pre infusion checks: clinical assessment, Blood tests, vital signs and side effects review happen before every cycle. Treatment is held or adjusted if blood counts or organ function fall below thresholds.
Step 5.
Drug compounding: Cytotoxic drugs are mixed by a trained oncology pharmacist in a sterile compounding suite that complies with USP 800 and Saudi FDA standards. This step is non-negotiable for patient safety.
Step 6.
Infusion: You are settled into a private or semi private day care chair. An oncology nurse stays close, giving premedications first, then the main infusion, while monitoring you continuously for any reaction.
Step 7.
Recovery and follow up: After a short observation period you go home with clear side effect guidance, supportive medication and a follow up plan, so you and your family always know what to expect next.
A typical chemotherapy course in Riyadh runs 4 to 8 cycles over 3 to 6 months. Immunotherapy and Hormonal therapy can extend to 12 to 24 months depending on how well the treatment is working.
Already have a treatment plan from your oncologist? Speak to IV One about administering it in Riyadh. We coordinate scheduling of cycles supportive care with your oncology team, so you can focus on getting through treatment.[1] [2]
Safety, Standards and Regulatory Oversight
Cancer infusion is high risk medication delivery. Errors can be catastrophic. IV one center regulatory framework is structured to prevent that risk through layered oversight.
The Saudi Food and Drug Authority regulates the import, registration, storage and dispensing of all oncology drugs.
The Saudi Ministry of Health sets clinical and operational standards for oncology services in both public and private settings.
CBAHI accreditation ensures that hospitals and day-care infusion centers comply with established healthcare quality and patient safety standards, encompassing medication management, infection control practices, workforce competency, patient identification processes, and other critical clinical and operational requirements.
The Council of Cooperative Health Insurance defines the minimum coverage scope for oncology treatment under the unified policy framework.
For patients, the practical signals of a safe oncology infusion centre are five. Onsite oncology pharmacist. Sterile compounding suite. Oncology certified nursing staff. Defined protocol for hypersensitivity reactions and extravasation. Direct escalation pathway to a tertiary oncology hospital.
IV One operates in compliance with each of these standards and quality indicators.
Costs, Insurance and Access in Riyadh
Cost is one of the most searched questions around oncology infusion therapy in Riyadh. The picture is layered.
For Saudi nationals, oncology care including infusion therapy is largely covered through the public health system at no direct cost.
For expatriate residents, coverage runs through mandatory employer provided health insurance under the CCHI unified policy. Most policies include oncology benefits, subject to category limits, network restrictions and pre approval requirements.
For self-pay patients, the cost of a single chemotherapy infusion cycle in a private Riyadh centre typically ranges from SAR 3,000 to SAR 25,000 depending on the regimen, with biologics and immunotherapy at the higher end. A full treatment course can range from SAR 30,000 to SAR 400,000 or more.
Three points are worth flagging for any patient navigating the financial side. First, most private insurance plans require pre-authorisation for each cycle. Second, biologic and immunotherapy agents often sit on a separate benefit category with stricter caps. Third, supportive medications and imaging between cycles are usually billed separately and can add 10 to 20 percent on top of headline drug costs.
The IV One billing team manages pre authorisation and direct billing with major Saudi insurers on behalf of patients.
How to Choose an Oncology Infusion Provider in Riyadh
Not all infusion centres are equivalent. The right choice depends on clinical need, but the evaluation criteria are consistent.
- Accreditation: Confirm CBAHI accreditation and, where available, JCI accreditation.
- Oncologist led care: Treatment plans should be designed and reviewed by a board certified medical oncologist/Hematologist
- Pharmacist oversight: An onsite oncology pharmacist who reviews every order is one of the strongest predictors of medication safety.
- Nursing standards Look for chemotherapy certified oncology nurses with documented competency assessments.
- Emergency capability: The centre should have onsite resuscitation capacity and a clear transfer pathway to a tertiary oncology hospital for serious adverse events.
- Continuity of care: The infusion provider should integrate with the treating oncologist, share records, and coordinate imaging, labs and follow up.
- Patient experience: Day care chair design, privacy, family accommodation, scheduling reliability and waiting times materially affect quality of life across a multi month treatment course.
Why Patients Choose IV One for Oncology Infusion in Riyadh
IV One Health Centre is a Saudi specialist infusion centre. We do not diagnose cancer or design treatment plans, that responsibility lies with your treating oncologist. What we do is deliver the treatment they have prescribed, with the same clinical standards as a hospital and a level of comfort and personal care that hospitals are often not built for.
Here is what our patients tell us makes the difference.
A faithful extension of your oncologist’s plan. We administer your prescribed regimen exactly as ordered, with oncology trained pharmacists checking every preparation and chemotherapy certified nurses delivering every infusion.
Safety you can verify. IV One operates under full Saudi Ministry of Health licensing, Saudi FDA pharmacy oversight and CBAHI aligned safety standards, with protocols you are welcome to ask about at any time.
A space designed around you. Private and semi private chairs, room for a family member or friend, calm lighting, refreshments and small comforts that matter on a long treatment day.
We do the running around. Our team works directly with your hospital oncologist and your insurer, sharing records and approvals so you are not carrying paperwork between clinics on a treatment day.
Supportive care in one place. Hydration, anti nausea, blood products and recovery infusions can be scheduled around your treatment cycles on referral, cutting down repeat trips and helping you bounce back faster.
Meet the IV One clinical team or book a confidential consultation.
Innovations Shaping Oncology Infusion in Riyadh
The oncology infusion landscape in Riyadh is changing quickly. Five trends matter most for patients and families planning treatment in 2026.
Subcutaneous reformulation of biologics. Several previously intravenous monoclonal antibodies are now available as subcutaneous injections, cutting chair time from hours to minutes. Adoption is accelerating in Riyadh’s leading centres.
Expansion of outpatient and day care models. New dedicated infusion centres are reducing the burden on hospital oncology wards and giving patients faster access to chair time.
Precision oncology integration. Biomarker driven treatment selection is now routine in Riyadh’s tertiary centres, improving response rates and reducing futile toxicity.
Oncology Infusion FAQ
What is oncology infusion therapy?
How long does a chemotherapy infusion take in IV one center?
Is chemotherapy painful?
How often will I need infusion sessions?
Can I work during chemotherapy?
Does insurance cover oncology infusion in Saudi Arabia?
What is the difference between chemotherapy and immunotherapy?
Can oncology infusions be given at home by IV one?
How do I choose the best oncology infusion centre in Riyadh?
Speak to IV One
Sources and references: American Cancer Society, American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), World Health Organization (WHO), Saudi Food and Drug Authority (SFDA), Saudi Ministry of Health (MOH), Saudi Central Board for Accreditation of Healthcare Institutions (CBAHI), Council of Cooperative Health Insurance (CCHI), Oncology Nursing Society (ONS), King Faisal Specialist Hospital and Research Centre.
Dr. Hamad ALAssaf
MD — Internal Medicine / Hematologist, IV One Health Centre